中药治疗银屑病的获益与安全性:系统评价再评价
该研究对14篇中药治疗银屑病的系统评价/Meta分析进行再评价,采用AMSTAR 2、ROBIS、PRISMA和GRADE工具评估方法学质量、偏倚风险、报告质量和证据质量。结果显示方法学与证据质量普遍偏低,仅33.33%结局为中等质量证据支持中药联合西药优于单用西药,不良事件发生率无差异,但中药优于西药的结论因结果不一致无法得出。
要点
- 中药联合西药治疗银屑病可能获益且安全性不劣于单用西药,但证据质量普遍偏低,结论需谨慎。
- 14篇系统评价中12篇(85.71%)方法学质量极低,7篇(50.00%)偏倚风险高,无高质量证据结局。
- 仅15个(33.33%)结局为中等质量证据支持联合治疗优于单用西药,中药单用优于西药的结论不成立。
核心结论
- 中药在银屑病辅助治疗中具有潜在获益和安全性,但因方法学和证据质量普遍偏低,结论应谨慎对待。
- 未来需开展高质量随机对照试验并提升相关系统评价质量以促进临床应用。
研究设计与样本
- 检索9个电子数据库(建库至2021年1月20日)及纳入系统评价的参考文献、方案注册库和灰色文献。
- 纳入14篇中药治疗银屑病的系统评价/Meta分析,涉及45个结局。
- 由两名评价者独立使用AMSTAR 2、ROBIS、PRISMA和GRADE工具进行评估。
主要发现
- 12篇(85.71%)系统评价/Meta分析经AMSTAR 2评价为极低质量。
- 7篇(50.00%)系统评价/Meta分析经ROBIS评价为高偏倚风险。
- PRISMA清单显示方案与注册及基金声明是主要报告缺陷。
- GRADE评价无高质量证据结局,仅15个(33.33%)结局为中等质量证据支持中药联合西药优于单用西药。
- 一般低质量证据显示联合治疗与单用西药在不良事件发生率上无差异,但中药优于西药的结论因结果不一致无法得出。
关键数值与推荐
- AMSTAR 2评价:12篇(85.71%)系统评价/Meta分析为极低质量。
- ROBIS评价:7篇(50.00%)系统评价/Meta分析为高偏倚风险。
- GRADE评价:无高质量证据结局,15个(33.33%)结局为中等质量证据。
临床怎么用
- 临床可考虑中药作为银屑病辅助治疗,但需向患者说明证据质量普遍偏低。
- 中药联合西药可能不增加不良事件发生率,但中药单用替代西药的证据不充分。
- 应优先参考中等质量证据支持的联合治疗方案,避免依据低质量证据做决策。
局限性
- 纳入的系统评价/Meta分析方法学质量和报告质量普遍偏低。
- 多数结局证据质量低或极低,且疗效评价结果不一致。
- 无高质量证据结局,限制了结论的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: In recent years, systematic reviews/meta-analyses (SRs/MAs) of Chinese herbal medicine (CHM) for psoriasis have continuously emerged. Their methods and evidence quality, however, are yet to be evaluated, and whether their conclusions can provide clinicians with reliable evidence is still debatable. Objectives: This overview aims to evaluate the methodological quality, risk of bias, and reporting quality of relevant SRs/MAs, as well as the current evidence of CHM for treating psoriasis. Methods: We searched nine electronic databases from their respective time of establishment to January 20, 2021, as well as the reference lists of the included SRs/MAs, protocol registries, and gray literature. Two reviewers independently used the following: A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, Risk of Bias in Systematic Reviews (ROBIS), the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), and Grades of Recommendations, Assessment, Development and Evaluation (GRADE) to evaluate the methodological quality, risk of bias, reporting quality, and evidence quality of the included SRs/MAs. Results: This review included 14 SRs/MAs involving 45 outcomes, of which 12 (85.71%) SRs/MAs had a very low quality evaluated by AMSTAR 2 and 7 (50.00%) SRs/MAs had a high risk of bias assessed by ROBIS. The protocol and registration and funding statements were the major reporting flaws according to the PRISMA checklist. The evaluation with the GRADE system demonstrated no outcome of high-quality evidence, and inconsistent efficacy evaluations were found in this overview. Only 15 (33.33%) outcomes were moderate-quality evidence, supporting the claim that CHM plus Western medicine (WM) was superior to WM. Generally low quality of evidence showed no difference in the incidence of adverse events between the combined therapy and WM. However, the conclusion that CHM was superior to WM cannot be drawn due to the inconsistent results. Conclusion: Despite that CHM has the potential benefit and safety in the adjuvant treatment of psoriasis, the conclusion should be treated with caution because of the generally low quality of methodology and evidence. In the future, high-quality randomized controlled trials (RCTs) should be carried out, and the quality of relevant SRs should also be improved to promote their clinical application.
引用
- Zhang J, Yu Q, Peng L, et al. Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews. Front Pharmacol. 2021. PMID: 34276371. doi:10.3389/fphar.2021.680172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。